Search Results - "Niwa, Rinpei"

The current status and prospects of antibody engineering for therapeutic use: focus on glycoengineering technology by Niwa, Rinpei, Satoh, Mitsuo

“…Monoclonal antibodies have demonstrated enormous potential as new classes of drugs that confer great benefits to patients, and more than 40 therapeutic…”
Get more information

Engineered therapeutic antibodies with improved effector functions by Kubota, Tsuguo, Niwa, Rinpei, Satoh, Mitsuo, Akinaga, Shiro, Shitara, Kenya, Hanai, Nobuo

“…In the past decade, more than 20 therapeutic antibodies have been approved for clinical use and many others are now at the clinical and preclinical stage of…”
Get full text

Novel cancer‐specific epidermal growth factor receptor antibody obtained from the serum of esophageal cancer patients with long‐term survival by Takagi‐Maeda, Sayaka, Yajima, Satoshi, Suzuki, Takashi, Usami, Katsuaki, Takahashi, Nobuaki, Niwa, Rinpei, Shimada, Hideaki

“…Although esophageal cancer has a poor prognosis after recurrence, some patients have shown long‐term survival despite recurrence. We hypothesized that…”
Get full text

Improving effector functions of antibodies for cancer treatment: Enhancing ADCC and CDC by Natsume, Akito, Niwa, Rinpei, Satoh, Mitsuo

“…As platforms for therapeutic agents, monoclonal antibodies (MAbs) have already been approved, and several MAbs have demonstrated clinical effectiveness in a…”
Get full text

Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma by RINPEI NIWA, SHOJI-HOSAKA, Emi, SAKURADA, Mikiko, SHINKAWA, Toyohide, UCHIDA, Kazuhisa, NAKAMURA, Kazuyasu, MATSUSHIMA, Kouji, UEDA, Ryuzo, HANAI, Nobuo, SHITARA, Kenya

“…Human IgG1 antibodies with low fucose contents in their asparagine-linked oligosaccharides have been shown recently to exhibit potent antibody-dependent…”
Get full text

Engineered anti‐CD20 antibodies with enhanced complement‐activating capacity mediate potent anti‐lymphoma activity by Natsume, Akito, Shimizu‐Yokoyama, Yukiko, Satoh, Mitsuo, Shitara, Kenya, Niwa, Rinpei

“…One of the major issues in current antibody therapy is insufficient efficacy. Various biological factors relating to the host’s immune system or tumor cells…”
Get full text

Enhancement of the Antibody-Dependent Cellular Cytotoxicity of Low-Fucose IgG1 Is Independent of FcγRIIIa Functional Polymorphism by Niwa, Rinpei, Hatanaka, Shigeki, Shoji-Hosaka, Emi, Sakurada, Mikiko, Kobayashi, Yukari, Uehara, Aya, Yokoi, Haruhiko, Nakamura, Kazuyasu, Shitara, Kenya

“…Purpose: The most common polymorphic variant of Fcγ receptor type IIIa (FcγRIIIa), FcγRIIIa-158F, has been associated with inferior clinical responses to…”
Get full text

Enhanced Natural Killer Cell Binding and Activation by Low-Fucose IgG1 Antibody Results in Potent Antibody-Dependent Cellular Cytotoxicity Induction at Lower Antigen Density by NIWA, Rinpei, SAKURADA, Mikiko, KOBAYASHI, Yukari, UEHARA, Aya, MATSUSHIMA, Kouji, UEDA, Ryuzo, NAKAMURA, Kazuyasu, SHITARA, Kenya

“…Purpose: Recent studies have revealed that fucose removal from the oligosaccharides of human IgG1 antibodies results in a significant enhancement of…”
Get full text

A Nonfucosylated Anti-HER2 Antibody Augments Antibody-Dependent Cellular Cytotoxicity in Breast Cancer Patients by SUZUKI, Eiji, NIWA, Rinpei, TOI, Masakazu, SAJI, Shigehira, MUTA, Mariko, HIROSE, Makiko, IIDA, Shigeru, SHIOTSU, Yukimasa, SATOH, Mitsuo, SHITARA, Kenya, KONDO, Masahide

“…Purpose: Removal of fucose residues from the oligosaccharides of human antibody is a powerful approach to enhance antibody-dependent cellular cytotoxicity…”
Get full text

Engineering Chinese hamster ovary cells to maximize effector function of produced antibodies using FUT8 siRNA by Mori, Katsuhiro, Kuni-Kamochi, Reiko, Yamane-Ohnuki, Naoko, Wakitani, Masako, Yamano, Kazuya, Imai, Harue, Kanda, Yutaka, Niwa, Rinpei, Iida, Shigeru, Uchida, Kazuhisa, Shitara, Kenya, Satoh, Mitsuo

“…We explored the possibility of converting established antibody‐producing cells to cells producing high antibody‐dependent cellular cytotoxicity (ADCC)…”
Get full text

Non-fucosylated therapeutic antibodies : the next generation of therapeutic antibodies by MORI, Katsuhiro, IIDA, Shigeru, NIWA, Rinpei, SHITARA, Kenya, SATOH, Mitsuo, YAMANE-OHNUKI, Naoko, KANDA, Yutaka, KUNI-KAMOCHI, Reiko, NAKANO, Ryosuke, IMAI-NISHIYA, Harue, OKAZAKI, Akira, SHINKAWA, Toyohide, NATSUME, Akihito

“…Therapeutic antibody IgG1 has two N-linked oligosaccharide chains bound to the Fc region. The oligosaccharides are of the complex biantennary type, composed of…”
Get full text

Enhanced Fc-Dependent Cellular Cytotoxicity of Fc Fusion Proteins Derived from TNF Receptor II and LFA-3 by Fucose Removal from Asn-Linked Oligosaccharides by Shoji-Hosaka, Emi, Kobayashi, Yukari, Wakitani, Masako, Uchida, Kazuhisa, Niwa, Rinpei, Nakamura, Kazuyasu, Shitara, Kenya

“…Fucose removal from complex-type oligosaccharide of human IgGs results in a major enhancement of Fc-dependent cellular cytotoxicity. The aim of this study was…”
Get full text

Fucose Removal from Complex-Type Oligosaccharide Enhances the Antibody-Dependent Cellular Cytotoxicity of Single-Gene-Encoded Bispecific Antibody Comprising of Two Single-Chain Antibodies Linked to the Antibody Constant Region by Natsume, Akito, Wakitani, Masako, Yamane-Ohnuki, Naoko, Shoji-Hosaka, Emi, Niwa, Rinpei, Uchida, Kazuhisa, Satoh, Mitsuo, Shitara, Kenya

“…Bispecific antibodies (bsAbs) have the potential to extend binding selectivity, increase avidity and exert potent cytotoxicity due to the combination of dual…”
Get full text

Optimizing Therapeutic Antibody Function: Progress with Fc Domain Engineering by Kaneko, Etsuji, Niwa, Rinpei

“…Since the establishment of monoclonal antibody production using hybridoma technology in the mid-1970s, there has been expanding progress and continuous…”
Get full text

Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities by Natsume, Akito, In, Mika, Takamura, Hiroyuki, Nakagawa, Tomoaki, Shimizu, Yukiko, Kitajima, Kazuko, Wakitani, Masako, Ohta, So, Satoh, Mitsuo, Shitara, Kenya, Niwa, Rinpei

“…Enhancement of multiple effector functions of an antibody may be a promising approach for antibody therapy. We have previously reported that fucose removal…”
Get full text

Establishment of FUT8 knockout Chinese hamster ovary cells: An ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity by Yamane-Ohnuki, Naoko, Kinoshita, Satoko, Inoue-Urakubo, Miho, Kusunoki, Machi, Iida, Shigeru, Nakano, Ryosuke, Wakitani, Masako, Niwa, Rinpei, Sakurada, Mikiko, Uchida, Kazuhisa, Shitara, Kenya, Satoh, Mitsuo

“…To generate industrially applicable new host cell lines for antibody production with optimizing antibody‐dependent cellular cytotoxicity (ADCC) we disrupted…”
Get full text

Optimizing Therapeutic Antibody Function by Kaneko, Etsuji, Niwa, Rinpei

“…Since the establishment of monoclonal antibody production using hybridoma technology in the mid-1970s, there has been expanding progress and continuous…”
Get full text

The therapeutic potential of a novel PSMA antibody and its IL-2 conjugate in prostate cancer by Sugimoto, Yoshiyuki, Hirota, Maiko, Yoshikawa, Kazuhiro, Sumitomo, Makoto, Nakamura, Kogenta, Ueda, Ryuzo, Niwa, Rinpei, Suzawa, Toshiyuki, Yamasaki, Motoo, Shitara, Kenya, Kato, Takashi, Nakamura, Kazuyasu

“…Prostate-specific membrane antigen (PSMA) is an attractive target for treatment of prostate cancer. Using the PSMA-recognizing mouse monoclonal antibody 2C9…”
Get full text

Strategy for technology development of antibody therapeutics by Takahashi, Nobuaki, Niwa, Rinpei, Nakano, Ryousuke, Tomizuka, Kazuma

Get more information

Nonfucosylated anti-CD20 antibody potentially induces apoptosis in lymphoma cells through enhanced interaction with FcγRIIIb on neutrophils by Nakagawa, Tomoaki, Natsume, Akito, Satoh, Mitsuo, Niwa, Rinpei

“…Abstract We demonstrate herein the augmentation of rituximab-mediated apoptosis in lymphoma cell lines by cross-linking with recombinant FcγRs, which is…”
Get full text